International Stem Cell Corp ISCO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.07
- Day Range
- $0.07–0.07
- 52-Week Range
- $0.05–0.15
- Bid/Ask
- $0.06 / $0.09
- Market Cap
- $568,311.62
- Volume/Avg
- 100 / 3,430
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.07
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 29
Valuation
|
Metric
|
ISCO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.07 |
Price/Cash Flow | 1.44 |
Price/Earnings
ISCO
Financial Strength
|
Metric
|
ISCO
|
|---|---|
Quick Ratio | 0.43 |
Current Ratio | 0.76 |
Interest Coverage | −3.92 |
Quick Ratio
ISCO
Profitability
|
Metric
|
ISCO
|
|---|---|
Return on Assets (Normalized) | −3.06% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −22.24% |
Return on Assets
ISCO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kvkmqjpdn | Cfgxb | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fcpzlrwy | Xjtszp | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jjrgfvqxz | Ylbqg | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rssjfkdq | Xrffhf | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Cmkxgng | Ftmh | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Drzvhkkw | Cqkp | $28.0 Bil | |||
| Moderna Inc
MRNA
| Tkddgvr | Fvqg | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Bbmqtdh | Nfl | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ghhbzrjq | Nlqbp | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Mxhqyhhmm | Sfgdzy | $12.6 Bil |
United States